Viatris - 45 Year Stock Price History | VTRS

Historical daily share price chart and data for Viatris since 1980 adjusted for splits and dividends. The latest closing stock price for Viatris as of June 13, 2025 is 8.92.
  • The all-time high Viatris stock closing price was 63.61 on April 24, 2015.
  • The Viatris 52-week high stock price is 13.55, which is 51.9% above the current share price.
  • The Viatris 52-week low stock price is 6.85, which is 23.2% below the current share price.
  • The average Viatris stock price for the last 52 weeks is 10.78.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Viatris Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2025 9.3382 12.0924 12.0924 7.1575 8.9200 -26.41%
2024 11.1855 10.6518 13.0173 9.5968 12.1216 19.68%
2023 9.2550 10.1468 10.9315 8.0967 10.1281 2.06%
2022 9.6644 12.1607 13.1790 7.4793 9.9239 -14.29%
2021 12.2670 15.5048 15.5048 10.3464 11.5787 -26.12%
2020 14.1297 17.2693 19.1092 11.0892 15.6720 -6.77%
2019 18.6437 23.3492 26.8448 14.0496 16.8094 -26.64%
2018 31.7101 36.0524 39.8408 21.9191 22.9143 -35.24%
2017 31.5315 32.7072 37.8671 24.7792 35.3833 10.90%
2016 36.3777 44.5574 45.2348 28.5509 31.9044 -29.44%
2015 48.3702 47.1248 63.6081 32.7490 45.2181 -4.08%
2014 41.8342 35.6091 49.0232 35.3415 47.1416 29.88%
2013 28.3367 23.1652 37.2148 23.0314 36.2949 58.11%
2012 19.5047 18.5238 23.6669 17.2610 22.9561 27.91%
2011 17.9629 18.1140 21.0995 13.5144 17.9467 1.56%
2010 16.2462 15.6553 19.4437 14.0998 17.6708 14.65%
2009 11.9194 8.3796 15.9229 8.2458 15.4128 86.35%
2008 9.7931 11.6077 12.8788 4.8254 8.2709 -29.66%
2007 15.0014 16.6577 18.8721 11.0808 11.7582 -29.13%
2006 17.4389 16.4357 20.4788 15.7483 16.5912 1.15%
2005 14.9136 14.2700 17.7061 12.6171 16.4028 14.17%
2004 16.5938 20.2899 20.8553 11.8977 14.3675 -29.58%
2003 17.5709 12.6676 22.7182 12.6676 20.4029 63.79%
2002 11.1534 12.7661 12.7661 8.8956 12.4571 -5.80%
2001 10.2583 8.5986 13.3691 7.3143 13.2245 50.74%
2000 8.8167 8.3593 11.0982 5.8503 8.7728 1.56%
1999 8.2408 10.1290 10.5511 5.9153 8.6379 -18.78%
1998 9.2313 6.6874 11.8230 5.9166 10.6355 52.39%
1997 5.9942 5.3897 8.2962 3.7782 6.9791 28.51%
1996 5.7225 7.3229 7.3229 4.5489 5.4306 -27.81%
1995 6.4757 5.4192 7.7730 5.2098 7.5229 33.04%
1994 4.8539 4.9443 6.1657 3.2604 5.6548 9.30%
1993 5.6722 6.1343 7.3862 4.1618 5.1737 -18.00%
1992 4.3560 4.0524 6.3131 3.1247 6.3096 55.23%
1991 2.6354 1.8529 4.0647 1.5965 4.0647 111.39%
1990 1.8278 2.1057 2.1721 1.3162 1.9228 -10.57%
1989 1.1253 0.7815 2.2119 0.6714 2.1500 175.11%
1988 0.8900 0.7653 1.1479 0.7134 0.7815 8.30%
1987 1.1832 0.9863 1.4631 0.6740 0.7216 -25.18%
1986 1.5271 1.5536 2.3303 0.9386 0.9645 -39.18%
1985 1.8054 2.1145 3.0855 1.1867 1.5859 -27.59%
1984 2.0060 1.6722 3.0316 1.1976 2.1901 27.67%
1983 1.6968 1.6075 2.7835 1.1867 1.7154 10.41%
1982 1.3565 1.4457 1.8664 0.7660 1.5536 6.67%
1981 1.2003 0.7120 2.4166 0.6150 1.4565 107.69%
Sector Industry Market Cap Revenue
Medical Medical Services $10.469B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $143.614B 26.94
Elevance Health (ELV) United States $86.883B 11.21
CVS Health (CVS) United States $85.338B 10.61
Cencora (COR) United States $57.282B 19.93
DiDi Global (DIDIY) China $22.826B 24.25
Natera (NTRA) United States $22.577B 0.00
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $13.669B 0.00
Solventum (SOLV) United States $12.768B 13.52
ICON (ICLR) Ireland $11.763B 10.94
CochLear (CHEOY) Australia $11.550B 0.00
Revvity (RVTY) United States $11.024B 18.97
Doximity (DOCS) United States $10.503B 48.63
HealthEquity (HQY) United States $9.059B 39.68
Avantor (AVTR) United States $8.906B 12.94
Medpace Holdings (MEDP) United States $8.572B 22.77
Sonic Healthcare (SKHHY) Australia $8.393B 0.00
Charles River Laboratories (CRL) United States $7.340B 14.38
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.361B 25.69
BrightSpring Health Services (BTSG) United States $3.724B 34.16
Sotera Health (SHC) United States $3.244B 18.44
Alignment Healthcare (ALHC) United States $2.956B 0.00
Surgery Partners (SGRY) United States $2.914B 37.90
Concentras Parent (CON) United States $2.749B 15.89
Organon (OGN) United States $2.610B 2.77
Ardent Health (ARDT) United States $1.881B 8.02
Premier (PINC) United States $1.858B 14.11
GeneDx Holdings (WGS) United States $1.842B 70.96
Progyny (PGNY) United States $1.803B 39.68
PACS (PACS) United States $1.573B 0.00
GoodRx Holdings (GDRX) United States $1.561B 31.21
Teladoc Health (TDOC) United States $1.203B 0.00
Pediatrix Medical (MD) United States $1.203B 9.15
Establishment Labs Holdings (ESTA) $1.083B 0.00
CareDx (CDNA) United States $1.035B 16.17
Ryman Healthcare (RYHTY) New Zealand $1.011B 0.00
Agilon Health (AGL) United States $0.890B 0.00
AMN Healthcare Services Inc (AMN) United States $0.826B 7.73
QDM (QDMI) Hong Kong, SAR China $0.763B 0.00
Nutex Health (NUTX) United States $0.679B 10.28
LifeMD (LFMD) United States $0.566B 0.00
Embecta (EMBC) United States $0.559B 3.76
Enhabit (EHAB) United States $0.495B 40.75
InnovAge Holding (INNV) United States $0.478B 0.00
Auna S.A (AUNA) Luxembourg $0.467B 10.52
SBC Medicals (SBC) United States $0.459B 0.00
Sonida Senior Living (SNDA) United States $0.453B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.411B 0.00
Performant Healthcare (PHLT) United States $0.255B 0.00
Oncology Institute (TOI) United States $0.220B 0.00
Beauty Health (SKIN) United States $0.193B 0.00
KindlyMD (KDLY) United States $0.150B 0.00
DocGo (DCGO) United States $0.148B 24.17
Pheton Holdings (PTHL) China $0.114B 0.00
So-Young (SY) China $0.097B 0.00
KindlyMD (NAKA) United States $0.083B 0.00
OncoCyte (OCX) United States $0.076B 0.00
Sera Prognostics (SERA) United States $0.064B 0.00
Basel Medical Group (BMGL) Singapore $0.064B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
Ascend Wellness Holdings (AAWH) United States $0.060B 0.00
IceCure Medical (ICCM) Israel $0.054B 0.00
Biodesix (BDSX) United States $0.042B 0.00
ModivCare (MODV) United States $0.042B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.028B 0.00
Intelligent Bio Solutions (INBS) United States $0.013B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
Co-Diagnostics (CODX) United States $0.009B 0.00
XWELL (XWEL) United States $0.005B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
INVO Fertility (IVF) United States $0.003B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
NewGenIvf Group (NIVF) Thailand $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00